{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:46:42Z","timestamp":1789631202391,"version":"build-2803163510"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>The effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) demonstrated in ROCKET AF needs to be confirmed in daily care. To evaluate effectiveness and safety of rivaroxaban therapy in SPAF patients in daily care, we used data from an ongoing, prospective, non-interventional registry of more than 2700 patients on novel oral anticoagulants in daily care. Between October 1, 2011 and February 28, 2013, a total of 1204 SPAF patients receiving rivaroxaban were enrolled. During a mean follow-up of 796.2 \u00b1 207.3 days, the combined endpoint of stroke\/transient ischaemic attack\/systemic embolism occurred at a rate of 2.03\/100 patient-years in the intention-totreat analysis (95 % confidence interval [CI] 1.5\u20132.7) and at 1.7\/100 patient-years in the on-treatment analysis (events within 3 days after last intake). On-treatment rates were higher in patients selected for 15 mg rivaroxaban (n=384) once daily [OD] compared with the 820 patients selected for 20 mg OD (2.7 [95 % CI 1.6\u20134.2] vs 1.25\/100 patient-years [95 % CI 0.8\u20131.9]). On treatment, major bleeding occurred at a rate of 3.0\/100 patient-years and significantly more often in patients receiving the 15 mg OD dose compared with the 20 mg OD dose (4.5 vs 2.4\/100 patient-years). Rivaroxaban treatment discontinuation occurred in a total of 277 patients during follow-up (12.0\/100 patientyears in Kaplan-Meier analysis). Our data contribute to the confirmation of effectiveness and relative safety of rivaroxaban in daily-care patients. Furthermore, rivaroxaban discontinuation rates were considerably lower than those reported for vitamin K antagonists.<\/jats:p>\n                  <jats:p>Supplementary Material to this article is available online at www.thrombosis-online.com.<\/jats:p>","DOI":"10.1160\/th15-10-0840","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T04:57:45Z","timestamp":1453352265000},"page":"939-949","source":"Crossref","is-referenced-by-count":82,"title":["Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation"],"prefix":"10.1160","volume":"115","author":[{"given":"Judith","family":"Hecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Marten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Keller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindy","family":"Helmert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Michalski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Werth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurtulus","family":"Sahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Tittl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"key":"10.1160\/TH15-10-0840-1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"10.1160\/TH15-10-0840-2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2292"},{"key":"10.1160\/TH15-10-0840-3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.5.1155"},{"key":"10.1160\/TH15-10-0840-4","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S41404"},{"key":"10.1160\/TH15-10-0840-5","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut083"},{"key":"10.1160\/TH15-10-0840-6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"10.1160\/TH15-10-0840-7","doi-asserted-by":"crossref","unstructured":"Piccini JP, et al. Management of major bleeding events in patients treated with rivaroxaban vs warfarin: results from the ROCKET AF trial. Eur Heart J 2014; Epub ahead of print","DOI":"10.1093\/eurheartj\/ehu083"},{"key":"10.1160\/TH15-10-0840-8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht557"},{"key":"10.1160\/TH15-10-0840-9","doi-asserted-by":"crossref","unstructured":"Beyer-Westendorf J, et al. Safety of switching from Vitamin-K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry. Br J Clin Pharmacol 2014; Epub ahead of print","DOI":"10.1111\/bcp.12391"},{"key":"10.1160\/TH15-10-0840-10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563577"},{"key":"10.1160\/TH15-10-0840-11","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-11-0954"},{"key":"10.1160\/TH15-10-0840-12","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-02-0116"},{"key":"10.1160\/TH15-10-0840-13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"10.1160\/TH15-10-0840-14","doi-asserted-by":"crossref","unstructured":"Beyer-Westendorf J, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015; Epub ahead of print","DOI":"10.1093\/europace\/euu319"},{"key":"10.1160\/TH15-10-0840-15","unstructured":"Graham DJ, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation 2014; Epub ahead of print"},{"key":"10.1160\/TH15-10-0840-16","doi-asserted-by":"crossref","unstructured":"Sorensen R, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. Br Med J Open 2013; 3","DOI":"10.1136\/bmjopen-2013-002758"},{"key":"10.1160\/TH15-10-0840-17","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.907140"},{"key":"10.1160\/TH15-10-0840-18","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22373"},{"key":"10.1160\/TH15-10-0840-19","doi-asserted-by":"crossref","unstructured":"Camm AJ, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2015; Epub ahead of print","DOI":"10.1093\/eurheartj\/ehv466"},{"key":"10.1160\/TH15-10-0840-20","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-06-0497"},{"key":"10.1160\/TH15-10-0840-21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1857"},{"key":"10.1160\/TH15-10-0840-22","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-06-0453"},{"key":"10.1160\/TH15-10-0840-23","doi-asserted-by":"crossref","unstructured":"Avgil-Tsadok M, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 2015; 115: Epub ahead of print","DOI":"10.1160\/TH15-03-0247"},{"key":"10.1160\/TH15-10-0840-24","doi-asserted-by":"crossref","unstructured":"Maura G, et al. Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban versus Vitamin K Antagonists: A French Nationwide Propensity-Matched Cohort Study. Circulation 2015; Epub ahead of print","DOI":"10.1161\/CIRCULATIONAHA.115.015710"},{"key":"10.1160\/TH15-10-0840-25","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00198-3"},{"key":"10.1160\/TH15-10-0840-26","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.121218"},{"key":"10.1160\/TH15-10-0840-27","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90187-7"},{"key":"10.1160\/TH15-10-0840-28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1997.tb00023.x"},{"key":"10.1160\/TH15-10-0840-29","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.933577"},{"key":"10.1160\/TH15-10-0840-30","doi-asserted-by":"crossref","unstructured":"Nelson WW, et al. Medication Persistence and Discontinuation of Rivaroxaban and Dabigatran Etexilate among Patients with Non-Valvular Atrial Fibrillation. Curr Med Res Opin 2015: 1-31","DOI":"10.1185\/03007995.2015.1074064"},{"key":"10.1160\/TH15-10-0840-31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03059.x"},{"key":"10.1160\/TH15-10-0840-32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.653048"},{"key":"10.1160\/TH15-10-0840-33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.937680"},{"key":"10.1160\/TH15-10-0840-34","doi-asserted-by":"crossref","unstructured":"Lauffenburger JC, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015; Epub ahead of print","DOI":"10.1161\/JAHA.115.001798"},{"key":"10.1160\/TH15-10-0840-35","doi-asserted-by":"crossref","unstructured":"Larsen TB, et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med 2014; 127: 1172-1178 e5","DOI":"10.1016\/j.amjmed.2014.07.023"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH15-10-0840.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T17:53:52Z","timestamp":1567533232000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH15-10-0840"}},"subtitle":["Results from the Dresden NOAC Registry"],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":35,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2017,10,12]]},"published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1160\/th15-10-0840","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726092468.793526310","asserted-by":"object"}]},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}